Drugs / BGB-16673
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06906809 | Apr → Oct 2025 | — | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT06776679 | Jan → Mar 2025 | — | BeiGene | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05294731 | May 2022 → Jan 2029 expected | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Richter transformation, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +3 | BeiGene | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07508995 | Aug 2026 → Jul 2031 expected | B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06970743 | May 2025 → Nov 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | BeOne Medicines | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | BeOne Medicines | Results BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026 beonemedicines.com ↗
Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. |
| 2025-07-31 | BeOne Medicines | Regulatory BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia beonemedicines.com ↗
The EMA’s CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. |
| 2025-06-26 | BeOne Medicines | Results BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day beonemedicines.com ↗
New clinical data from CaDAnCe-101 highlight the promise of BGB-16673, a potential first-in-class BTK degrader, for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL). |
| 2025-06-12 | BeOne Medicines | Results BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 beonemedicines.com ↗
BTK degrader BGB-16673 shows strong early results in hard-to-treat populations |
| 2024-12-09 | BeOne Medicines | Results BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets beonemedicines.com ↗
Data for BTK degrader BGB-16673 from phase 1/2 study highlight its potential in both treatment-resistant CLL and other B-cell malignancies representing high unmet needs |
| 2024-11-05 | BeOne Medicines | Results BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 beonemedicines.com ↗
Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673 |
| 2024-10-16 | BeOne Medicines | Results BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 beonemedicines.com ↗
Additional presentations demonstrate our continued commitment to developing and evaluating new treatment options for Waldenström’s macroglobulinemia patients and include results from Phase 1 studies of our BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax. |
| 2024-08-26 | BeOne Medicines | Regulatory BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL beonemedicines.com ↗ |
| 2024-05-14 | BeOne Medicines | Results BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 beonemedicines.com ↗
Phase 1/2 results for BTK degrader BGB-16673 showcasing encouraging efficacy and tolerability, including in BTK inhibitor resistant disease |
| 2023-11-28 | BeOne Medicines | Results BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023 beonemedicines.com ↗
First presentation of data from ongoing, first-in-human study of BeiGene’s novel BTK degrader, BGB‑16673, demonstrating a tolerable safety profile and notable clinical responses in heavily pre-treated patients |
| 2023-06-09 | BeOne Medicines | Results BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress beonemedicines.com ↗
Early results for BTK-targeted CDAC (BGB-16673) and BCL-2 inhibitor (BGB-11417) in various B-cell malignancies illustrate promise of pipeline |
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-16673 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06906809 ↗ |
| Route | Oral | “BGB-16673 will be orally administered.” NCT05294731 ↗ |
| Target | BTK | “BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader” NCT05294731 ↗ |